Mingdao Haoyue Biotechnology

Chongqing Mingdao Haoyue Biotechnology is a clinical-stage biopharmaceutical joint venture established by Ausper Biopharma (AusperBio) and partners. Founded in 2021, the company focuses on the development of innovative intranasal therapies for respiratory viral infections, with a primary focus on COVID-19. Its lead pipeline candidates include MY-586 and A8G6, which are intranasal formulations of neutralizing monoclonal antibodies targeting the SARS-CoV-2 spike glycoprotein. These therapies are designed to deliver localized protection at the primary site of viral entry in the nasal cavity. Mingdao Haoyue Biotechnology collaborates with CDMO partners like AsymBio to advance its clinical candidates through development and manufacturing.